Ablynx in Phase 1 study of therapy for RSV

Tuesday 13 December 2011

Ablynx NV has started a Phase 1 study in healthy volunteers of an antibody-derived therapeutic protein for the treatment of respiratory syncytial viral infections. To date, there is only one approved antibody therapeutic for this disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium